ArticleJournal of virology2004
Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Article
- Rhabdoviruses as vectors for vaccines and therapeutics.Current opinion in virology · 2020Review
- Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.Journal of virology · 2020Article
- On the stability of sequences inserted into viral genomes.Virus evolution · 2019Review
- Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.Journal of virology · 2017Article
- Toll-Like Receptor 9 Activation Rescues Impaired Antibody Response in Needle-free Intradermal DNA Vaccination.Scientific reports · 2016Article
- Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.Clinical and vaccine immunology : CVI · 2014Article
- Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.Antiviral research · 2014Article
- Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.Molecular therapy. Methods & clinical development · 2014Article
- Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.Journal of virology · 2014Article
- Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.Virology journal · 2013Article
- A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.Journal of virology · 2013Article
- The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Journal of virology · 2012Article
- Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.PLoS neglected tropical diseases · 2012Article
- New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.Antiviral therapy · 2012Review
- A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region.Journal of virology · 2011Article
- Recombinant vaccines against the mononegaviruses--what we have learned from animal disease controls.Virus research · 2011Review
- The current status and future directions of myxoma virus, a master in immune evasion.Veterinary research · 2011Review
- Development and Applications of VSV Vectors Based on Cell Tropism.Frontiers in microbiology · 2011Article
- Progress in filovirus vaccine development: evaluating the potential for clinical use.Expert review of vaccines · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We generated an attenuated, recombinant vesicular stomatitis virus (VSV) expressing high levels of the cottontail rabbit papillomavirus (CRPV) L1 protein from an upstream site in the VSV genome. Rabbits vaccinated once with this VSV-L1 recombinant produced high levels of anti-L1 antibody and were completely protected against papilloma formation after challenge with CRPV. In contrast, animals vaccinated only once with a VSV vector expressing lower levels of L1 from a downstream site in the VSV genome generated lower levels of L1 antibody and demonstrated only incomplete protection from papilloma formation after challenge. We conclude that the level of L1 protein expression is critical in generating complete immunity with a single-dose vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.